Systemic lupus erythematosus
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
chronic disease |
| gptkbp:abbreviation |
SLE
|
| gptkbp:affects |
gptkb:skin
brain heart lungs kidneys joints |
| gptkbp:cause |
unknown
|
| gptkbp:complication |
gptkb:cardiovascular_disease
thrombosis infections lupus nephritis neuropsychiatric lupus |
| gptkbp:diagnosedBy |
gptkb:ANA_test
clinical criteria biopsy |
| gptkbp:field |
rheumatology
|
| gptkbp:firstDescribed |
gptkb:Charles_Louis_Alphonse_Laveran
|
| https://www.w3.org/2000/01/rdf-schema#label |
Systemic lupus erythematosus
|
| gptkbp:ICD-10_code |
gptkb:M32
|
| gptkbp:onset |
typically ages 15-45
|
| gptkbp:prevalence |
more common in women
more common in African, Asian, and Hispanic populations |
| gptkbp:relatedTo |
gptkb:systemic_sclerosis
gptkb:antiphospholipid_syndrome Sjogren's syndrome |
| gptkbp:riskFactor |
genetic predisposition
female sex hormonal factors environmental triggers |
| gptkbp:signature |
hematologic disorder
serositis discoid rash immunologic disorder malar rash renal disorder |
| gptkbp:subspecies |
drug-induced lupus
discoid lupus erythematosus neonatal lupus |
| gptkbp:symptom |
fever
fatigue joint pain hair loss photosensitivity skin rash oral ulcers |
| gptkbp:treatment |
gptkb:NSAIDs
antimalarial drugs biologics corticosteroids immunosuppressants |
| gptkbp:bfsParent |
gptkb:Lupus
|
| gptkbp:bfsLayer |
6
|